Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
|
|
IDEAYA Biosciences, Inc. (IDYA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/19/2022 |
8-K
| Asset disposition |
| 07/12/2021 |
8-K
| Asset disposition|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : July 7, 2021 IDEAYA Biosciences, Inc. Delaware 001-38915 47-4268251 7000 Shoreline Court, Suite 350 South San Francisco, California 94080 Registrant's telephone number, including area code: 443-6209 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐...",
"Underwriting Agreement, among IDEAYA Biosciences, Inc. and J.P. Morgan Securities LLC, Citigroup Global Markets Inc., and Jefferies LLC, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP" |
|
| 06/22/2020 |
8-K
| Quarterly results |
|
|